ReviewGastroenterology2017
Gastrointestinal Complications of Obesity.
Review in Gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- European Association for the Study of Obesity (EASO) Position Statement on Medical Nutrition Therapy for the Management of Individuals with Overweight or Obesity and Cancer.Obesity facts · 2025Guideline
- Pooled it
- Association between physical activity and risk of gastroesophageal reflux disease: A systematic review and meta-analysis.Journal of sport and health science · 2024Pooled it
- Pooled it
- Gastroesophageal reflux disease and non-alcoholic fatty liver disease: a two-sample Mendelian randomization combined with meta-analysis.Scientific reports · 2024Pooled it
- Economic costs of obesity: a systematic review.International journal of obesity (2005) · 2024Pooled it
- Body Mass Index and Risk of Gastric Cancer in Asian Adults: A Meta-Epidemiological Meta-Analysis of Population-Based Cohort Studies.Cancer research and treatment · 2020Pooled it
- Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials.Diabetes, obesity & metabolism · 2025Trial
- Clinical manifestation, lifestyle, and treatment patterns of chronic erosive gastritis: A multicenter real-world study in China.World journal of gastroenterology · 2024Trial
- Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.Diabetes, obesity & metabolism · 2022Trial
- Review
- Perioperative and Oncological Outcomes of Colorectal Cancer Surgery in Obese Patients: A Multicenter Retrospective Study.Annals of gastroenterological surgery · 2026Article
- High-Fat Diet-Induced Obesity Enhances Small Intestinal Glucose and NaCl Absorption Through Selective Transporter Reprogramming.International journal of molecular sciences · 2026Article
- Article
- Agent- and Dose-Specific Intestinal Obstruction Safety of GLP-1 Receptor Agonists and SGLT2 Inhibitors: A Network Meta-Analysis of Randomized Trials.International journal of molecular sciences · 2026Article
- Endoscopic ultrasound strain elastography in MASLD: Evaluation against transient elastography and non-invasive markers.Hepatology forum · 2026Article
- Enteric Glial Cell Culture to Mimic In Vivo Obesity and Neurodegenerative Disorders.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Global, regional, and national levels of maternal mortality, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.BMC pregnancy and childbirth · 2025Article
- Gastric motility and its association with adiposity and metabolic health in a cohort of Sri Lankan office workers.World journal of gastrointestinal pathophysiology · 2025Article
- Global, regional, and national burden of gallbladder and biliary tract diseases: A systematic analysis of prevalence, incidence, deaths, and disability-adjusted life years with projections to 2050.Annals of hepato-biliary-pancreatic surgery · 2025Article
51 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Obesity usually is associated with morbidity related to diabetes mellitus and cardiovascular diseases. However, there are many gastrointestinal and hepatic diseases for which obesity is the direct cause (eg, nonalcoholic fatty liver disease) or is a significant risk factor, such as reflux esophagitis and gallstones. When obesity is a risk factor, it may interact with other mechanisms and result in earlier presentation or complicated diseases. There are increased odds ratios or relative risks of several gastrointestinal complications of obesity: gastroesophageal reflux disease, erosive esophagitis, Barrett's esophagus, esophageal adenocarcinoma, erosive gastritis, gastric cancer, diarrhea, colonic diverticular disease, polyps, cancer, liver disease including nonalcoholic fatty liver disease, cirrhosis, hepatocellular carcinoma, gallstones, acute pancreatitis, and pancreatic cancer. Gastroenterologists are uniquely poised to participate in the multidisciplinary management of obesity as physicians caring for people with obesity-related diseases, in addition to their expertise in nutrition and endoscopic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.